Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.

BMC Cancer · 2018 · PMC5941622 · PMID 29739364

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the enhanced tumor growth inhibition did not reach statistical significance between the selumetinib and the combination treatment group, in the combination group the variance between relative tumor volumes was significantly lower than in the selumetinib group ( p = 0.017, F-test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.